Late-onset neutropenia induced by anti-B cell therapy with rituximab in patients with ANCA-associated systemic vasculitis

In the last decade, anti-neutrophil cytoplasmic antibodies (ANCA)-associated systemic vasculitis (SV) has been treated with the anti-B-cell drug, rituximab (RTM) both for induction and maintenance therapy. One of the problems of the treatment with RTM in patients with ANCA-SV is the risk of late-ons...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	T. V. Beketova, I. Yu. Popov, V. V. Babak
Format:	Artigo
Sprache:	Russo
Veröffentlicht:	IMA-PRESS LLC 2022-06-01
Schriftenreihe:	Современная ревматология
Schlagworte:	neutropenia rituximab b cells antineutrophil cytoplasmic antibodies vasculitis
Online-Zugang:	https://mrj.ima-press.net/mrj/article/view/1295
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!